Skip to main content
In stock|Targeted Therapy (Antibody)

Olaratumab

Oncology TypeSolid Tumour (Sarcoma/Neuroblastoma)
Drug Class / MechanismPDGFR / GD2 Targeting Agent
No Image
Description

Olaratumab is classified as a PDGFR / GD2 Targeting Agent, sourced for use within our Targeted Therapy (Antibody) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy (Antibody)
Oncology TypeSolid Tumour (Sarcoma/Neuroblastoma)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3